Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.24.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:    
Net loss $ (10,488) $ (3,603)
Reconciliation of net loss to net cash used in operating activities:    
Share based compensation 906 649
Change in fair value of warrant liability (4,258) (5,580)
Issuance of Stock Under Founders Agreement 371 526
Common Stock, Issued to Fortress, Value 72 0
Issuance of Stock for Licenses Acquired 1,230 0
Research and Development License, Acquired Expense 3,000 0
License Expenses Paid In Kind 6 4
Changes in operating assets and liabilities:    
Other receivables - related party 0 90
Prepaid expenses and other current assets 70 (30)
Net cash and cash equivalents used in operating activities (9,451) (7,596)
Cash flows from investing activities:    
Purchase of research and development licenses (3,000) 0
Net cash used in investing activities (3,000) 0
Cash flows from financing activities:    
Proceeds from issuance of common stock, warrants, and pre-funded warrants, net of issuance costs 7,525 11,497
Repurchase of common stock held by InvaGen 0 (1,104)
Proceeds from exercise of warrants 1 148
Net cash provided by financing activities 7,526 10,541
Net change in cash and cash equivalents (4,925) 2,945
Cash and cash equivalents, beginning of period 6,708 3,763
Cash and cash equivalents, end of period 1,783 6,708
Supplement disclosure of non-cash information:    
Receipt of interest in Baergic from Fortress 0 99
Unpaid offering costs 0 14
Related Party [Member]    
Changes in operating assets and liabilities:    
Accounts payable and accrued expenses (662) 385
Nonrelated Party [Member]    
Changes in operating assets and liabilities:    
Accounts payable and accrued expenses $ 302 $ (37)